Provided by Tiger Trade Technology Pte. Ltd.

Lineage

38.78
-0.0100-0.03%
Post-market: 38.780.00000.00%19:30 EDT
Volume:719.41K
Turnover:28.00M
Market Cap:8.81B
PE:-53.86
High:39.63
Open:39.63
Low:38.67
Close:38.79
52wk High:45.75
52wk Low:31.33
Shares:227.08M
Float Shares:57.19M
Volume Ratio:0.92
T/O Rate:1.26%
Dividend:2.12
Dividend Rate:5.47%
EPS(TTM):-0.7200
EPS(LYR):-0.4300
ROE:-2.04%
ROA:0.75%
PB:1.12
PE(LYR):-90.19

Loading ...

Lineage chairman buys $987.6K in common stock

TIPRANKS
·
Yesterday

Lineage Co-Executive Chairman Kevin Patrick Marchetti Acquires USD 987,555 of Common Shares

Reuters
·
Yesterday

Lineage is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Sep 01

Lineage Price Target Cut to $44.00/Share from $46.00 by Piper Sandler

Dow Jones
·
Aug 28

Morgan Stanley Sticks to Their Hold Rating for Lineage, Inc. (LINE)

TIPRANKS
·
Aug 25

Lineage Cell Therapeutics management to meet with B. Riley

TIPRANKS
·
Aug 25

Analysts Have Conflicting Sentiments on These NA Companies: Harrow Health (HROW) and Lineage, Inc. (LINE)

TIPRANKS
·
Aug 20

KARMAN LINE ACQUISITION CORP. Announces Pricing of $200 Million Initial Public Offering

GlobeNewswire
·
Aug 18

Lineage Seen Benefiting From Improving Industry Conditions, RBC Capital Markets Says

MT Newswires Live
·
Aug 17

RBC Raises Price Target on Lineage to $48 From $44, Keeps Outperform Rating

MT Newswires Live
·
Aug 17

Lineage, Inc. : RBC Raises Target Price to $48 from $44

THOMSON REUTERS
·
Aug 17

Should Widening Losses Despite Higher Sales in Q2 2026 Require Action From Lineage (LINE) Investors?

Simply Wall St.
·
Aug 16

Lineage is Maintained at Neutral by Citigroup

Dow Jones
·
Aug 14

Lineage Maintained at Buy with Unchanged $3 Target as Cell Therapy Pipeline and DOSED SCI Trial Advance

TIPRANKS
·
Aug 13

Lineage CFO Robb LeMasters Buys 20,000 Shares for $826,638

Reuters
·
Aug 11

Lineage, Inc. Earnings Call Signals Cautious Upside

TIPRANKS
·
Aug 10

Stronger NOI Guidance Amid Wider Losses Could Be A Game Changer For Lineage (LINE)

Simply Wall St.
·
Aug 08

Lineage Cell Therapeutics Balances Progress and Risk

TIPRANKS
·
Aug 08

Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)

TIPRANKS
·
Aug 07

Lineage Cell Therapeutics Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.069M Miss $1.531M Estimate

Benzinga Earnings
·
Aug 07